数据
资源
版本对比
免费注册
预约演示
免费注册
Insulet
Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands
2024-06-20
·
BioSpace
Following a successful limited market release, the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now fully available with
Dexcom
G6 and Abbott FreeStyle Libre 2 Plus in these countries ACTON, Mass.--(BUSINESS WIRE)--
Insulet Corporation
(NASDAQ: PODD) (
Insulet
or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Omnipod 5, compatible with both
Dexcom
G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor (CGM) sensors, is now fully available in the U.K. and the Netherlands for individuals aged two years and older with
type 1 diabetes
. Omnipod 5 is the first and only tubeless automated insulin delivery (AID) system integrated with both of the leading CGM sensor brands,
Dexcom
and Abbott FreeStyle Libre. “Expanding global access to Omnipod 5 is one of our top priorities. With the exciting, updated compatibility with both the Abbott FreeStyle Libre 2 Plus and the
Dexcom
G6 sensors, thousands more people with
diabetes
can enjoy the incredible freedom of tubeless, automated insulin delivery without having to change their CGM sensor brand. This is a game-changer for
diabetes
management,” said Patrick Crannell,
Insulet
Senior Vice President and International General Manager. Omnipod 5 is the first tubeless, waterproof1 AID system with proactive glucose control. The System is designed to be customer-centric and aims to deliver exceptional ease of use. It has demonstrated strong clinical results including lower A1c and improved time in range, while maintaining low time in
hypoglycemia.2,3
“Pod therapy is great because it is tubeless, and easy to use,” said Dion Screever, an 18-year-old student from the Netherlands. “When I started on Omnipod 5, I immediately noticed that my blood sugar was in range with much less effort from me, because of the automated insulin delivery technology. As someone who has lived with
type 1 diabetes
for nine years, Omnipod 5 has been life changing, giving me more freedom to live the way I want to.” Multiple sensor integrations including
Dexcom
G6 and Abbott FreeStyle Libre 2 Plus give prescribers greater flexibility when recommending a sensor for their patients and make it simple to begin AID therapy with Omnipod 5. Customers can select the sensor they would like to connect to Omnipod 5 during the setup process. Professor Partha S. Kar,
Type 1 Diabetes
and Technology Lead at NHS England and a consultant endocrinologist at Portsmouth Hospitals NHS Trust said, “The recent integration of Omnipod 5 with the FreeStyle Libre 2 Plus sensor will allow the life changing benefits of AID to be brought to many more people throughout the U.K., and also in the Netherlands. This is an exciting next step on this incredible journey to simplify life for people with
type 1 diabetes
.” To learn more or to get started, visit the Omnipod website. 1 The Pod has an IP28 rating for up to 7.6 meters (25 feet) for 60 minutes. The Omnipod® 5 controller is not waterproof. The
Dexcom
G6 sensor and transmitter are water-resistant and may be submerged under 2.4 meters (8 feet) of water for up to 24 hours without failure when properly installed. The FreeStyle Libre 2 Plus sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes. 2 Sherr JL, et al.
Diabetes
Care (2022). Study in 80 people with
type 1 diabetes (T1D)
aged 2 - 5.9 years involving two weeks standard
diabetes
therapy followed by three months Omnipod 5 use in Automated Mode. 3 Brown et al.
Diabetes
Care (2021). Study in 240 people with
T1D
aged 6 - 70 years involving two weeks standard
diabetes
therapy followed by three months Omnipod 5 use in Automated Mode. About
Insulet Corporation
:
Insulet Corporation
(NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with
diabetes
and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional
insulin
delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop
insulin
delivery, without the need to see or handle a needle.
Insulet
’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be fully controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller.
Insulet
also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com. ©2024
Insulet Corporation
. Omnipod is a registered trademark of
Insulet Corporation
. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission.
Dexcom
is a registered trademark of
Dexcom, Inc.
and used with permission. All other trademarks are the property of their respective owners. View source version on businesswire.com: Contacts Investor Relations: Deborah R. Gordon Vice President, Investor Relations (978) 600-7717 dgordon@insulet.com Media: Angela Geryak Wiczek Senior Director, Corporate Communications (978) 932-0611 awiczek@insulet.com Source:
Insulet Corporation
View this news release online at:
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Insulet Corp.
DexCom, Inc.
适应症
1型糖尿病
糖尿病
低血糖
靶点
-
药物
NNC0268-0965
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务